TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06926595: Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention

Sponsor: Milton S. Hershey Medical Center · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 41 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06926595 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06926595 Rescue Dossier →